Blinatumomab for Minimal Residual Disease (MRD) in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Median Overall Survival (OS) Is Not Reached in Complete MRD Responders at a Median Follow-up of 53.1 Months

被引：14

作者：

Goekbuget, Nicola ^{[1
]}

Dombret, Herve ^{[2
,3
]}

Zugmaier, Gerhard ^{[4
]}

Bonifacio, Massimiliano ^{[5
]}

Graux, Carlos ^{[6
]}

Faul, Christoph ^{[7
,8
]}

Topp, Max S. ^{[9
]}

Brueggemann, Monika ^{[10
]}

Taylor, Kate ^{[11
]}

Bargou, Ralf ^{[12
]}

机构：

[1] Goethe Univ, Dept Med Hematol Oncol 2, Frankfurt, Germany

[2] Univ Hop St Louis, Hematol, Paris, France

[3] AP HP, Paris, France

[4] Amgen Res Munich GmbH, Munich, Germany

[5] Univ Verona, Sect Hematol, Dept Med, Verona, Italy

[6] Catholic Univ Louvain, CHU UCL Namur Godinne, Yvoir, Belgium

[7] Univ Klinikum Tubingen, Univ Hosp, Tubingen, Germany

[8] Univ Klinikum Tubingen, Comprehens Canc Ctr Tubingen, Tubingen, Germany

[9] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[10] Univ Klinikum Schleswig Holstein, Dept Internal Med 2, Campus Kiel, Kiel, Germany

[11] Amgen Ltd, Cambridge, England

[12] Uniklinikum Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany

来源：

关键词：

D O I：

10.1182/blood-2018-99-111516

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

554

引用

页数：3